Opus Genetics is trading 8.2% up at $4.36, with biotech-sector momentum the strongest explanation.
- No newly identified company-specific announcement was reported on August 25, 2026; XBI rose 2.06% during regular trading alongside a broader market rally.
- The last major clinical update, Phase 3 enrollment completion for OPGx-LCA5, was announced August 3.
- Recent inducement grants and second-quarter results predate the move; trading activity is elevated, but volume data was unavailable.